Friday, April 28, 2017

BRIEF-Alder Biopharmaceuticals says presentation of positive data from Phase 2B clinical trial evaluating Eptinezumab for prevention of migraine

* Eptinezumab emerging clinical profile suggests migraine

preventative benefit achieved as soon as 24-48 hours after

single infusion

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)